Andrea Cercek1, Taryn M Boucher2, Jill S Gluskin3, Ariel Aguiló2, Joanne F Chou4, Louise C Connell2, Marinela Capanu4, Diane Reidy-Lagunes2, Michael D'Angelica5, Nancy E Kemeny2. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. cerceka@mskcc.org. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. METHODS: A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies. RESULTS: One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents). Fifty seven patients had LM-only and 53 patients had LM and low volume extrahepatic metastases (LME). Patients with LM-only and LME had a response rate (RR) of 33% and 36%, median survival of 20 months and 11.4 months, respectively. Patients with LM-only had progression free survival of 6 months and hepatic progression free survival of 7.56 months. In a secondary analysis, 46 patients were RECIST-refractory to all standard therapies: LM-only (n = 24) and LME (n = 22). LM-only and LME had a RR of 29% and 36%, and median survival 17.2 months and 9.1 months, respectively. CONCLUSIONS: Patients with refractory mCRC LM can achieve a response to HAI resulting in antitumor activity and improvement in survival. Responses are rarely seen in such heavily treated patients with systemic therapy alone, suggesting a regional directed approach is useful. J. Surg. Oncol. 2016;114:655-663.
BACKGROUND AND OBJECTIVES: To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. METHODS: A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies. RESULTS: One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents). Fifty seven patients had LM-only and 53 patients had LM and low volume extrahepatic metastases (LME). Patients with LM-only and LME had a response rate (RR) of 33% and 36%, median survival of 20 months and 11.4 months, respectively. Patients with LM-only had progression free survival of 6 months and hepatic progression free survival of 7.56 months. In a secondary analysis, 46 patients were RECIST-refractory to all standard therapies: LM-only (n = 24) and LME (n = 22). LM-only and LME had a RR of 29% and 36%, and median survival 17.2 months and 9.1 months, respectively. CONCLUSIONS:Patients with refractory mCRC LM can achieve a response to HAI resulting in antitumor activity and improvement in survival. Responses are rarely seen in such heavily treated patients with systemic therapy alone, suggesting a regional directed approach is useful. J. Surg. Oncol. 2016;114:655-663.
Authors: N Kemeny; M Gonen; D Sullivan; L Schwartz; F Benedetti; L Saltz; J Stockman; Y Fong; W Jarnagin; J Bertino; W Tong; P Paty Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu Journal: N Engl J Med Date: 2015-05-14 Impact factor: 91.245
Authors: David J Kerr; Colin S McArdle; Jonathan Ledermann; Irving Taylor; David J Sherlock; Peter M Schlag; John Buckels; David Mayer; Dionne Cain; Richard J Stephens Journal: Lancet Date: 2003-02-01 Impact factor: 79.321
Authors: Mohamed Bouchahda; René Adam; Sylvie Giacchetti; Denis Castaing; Catherine Brezault-Bonnet; Dominique Hauteville; Pasquale F Innominato; Christian Focan; David Machover; Francis Lévi Journal: Cancer Date: 2009-11-01 Impact factor: 6.860
Authors: N Kemeny; K Seiter; D Niedzwiecki; D Chapman; E Sigurdson; A Cohen; J Botet; P Oderman; P Murray Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: Nancy E Kemeny; Fidel D Huitzil Melendez; Marinela Capanu; Philip B Paty; Yuman Fong; Lawrence H Schwartz; William R Jarnagin; Dina Patel; Michael D'Angelica Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous Journal: Radiology Date: 2015-08-12 Impact factor: 11.105
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Peixian Zhang; Lan Shi; Linjing Song; Yi Long; Kehua Yuan; Wanbao Ding; Lei Deng Journal: Cancer Manag Res Date: 2020-03-09 Impact factor: 3.989